News | Women's Health | June 29, 2015

Breast Cancer Treatment with Fewer Potential Side Effects has Equally Good Patient Outcomes

UCLA study finds partial breast irradiation produces similar results to whole breast irradiation, with treatment reduced to one week

UCLA, breast cancer, partial breast irradiation, Mitchell Kamrava

June 29, 2015 - Women diagnosed with breast cancer and treated with one week of partial breast radiation after surgical tumor removal saw no increase in cancer recurrence or difference in cosmetic outcomes, according to a new UCLA study. Subjects were compared to women who received radiation of the entire breast for a period of up to six weeks after surgery. The study is one of the largest ever done on partial breast irradiation.

The study lasted two decades and was led by Mitchell Kamrava, M.D., an assistant professor of radiation oncology at UCLA and member of the Jonsson Comprehensive Cancer Center. Kamrava and his team found that with partial breast irradiation, the total length of treatment can be reduced to a week because the smaller area of treatment allows for a higher dosage per treatment. Additionally, because partial breast radiation is more targeted, there is less exposure to vital organs like the lungs and the heart.

The new treatment, formally known as accelerated partial breast irradiation with interstitial multicatheter brachytherapy, works by radiating only breast tissue in and around the area where the tumor was removed. The current standard of care, called whole breast conservation therapy, involves irradiating the entire breast after surgery, usually over the course of five to seven weeks. This results in prolonged exposure to radiation and can potentially lead to more side effects.

"This gives us confidence there is a group of women who are suitable candidates for partial breast radiation and more women should discuss this treatment option with their doctors," said Kamrava.

The study followed more than 1,000 women who received partial breast irradiation after surgery, with an average follow-up of about seven years.

The next phase for Kamrava and his team will be to analyze the results of randomized trials comparing whole breast versus partial breast irradiation.

For more information: www.cancer.ucla.edu

Related Content

Henry Ford Hospital's ViewRay MRIdian linear accelerator system allows real-time MRI-guided radiotherapy.

Henry Ford Hospital's ViewRay MRIdian linear accelerator system allows real-time MRI-guided radiotherapy.

Feature | Henry Ford Hospital | May 21, 2019 | Dave Fornell, Editor
Henry Ford Hospital thought leaders regularly speak at the radiation oncology and radiology conferences about new res
Varian Acquiring Cancer Treatment Services International
News | Radiation Therapy | May 21, 2019
Varian Medical Systems announced it has entered into a definitive agreement to acquire India’s Cancer Treatment...
Videos | Radiation Therapy | May 21, 2019
This is a walk through of the ViewRay MRIdian MRI-guided radiotherapy system installed at ...
Partial Breast Irradiation Effective, Convenient Treatment Option for Low-Risk Breast Cancer
News | Radiation Therapy | May 20, 2019
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast...
Managing Architectural Distortion on Mammography Based on MR Enhancement
News | Mammography | May 15, 2019
High negative predictive values (NPV) in mammography architectural distortion (AD) without ultrasonographic (US)...
New Method Improves Ability to Measure and Maximize Radiation Therapy Dose
News | Radiation Therapy | May 14, 2019
Delivering just the right dose of radiation for cancer patients is a delicate balance in their treatment regime....
Sponsored Content | Videos | Radiation Oncology | May 13, 2019
At ASTRO 2018, Accuray showcased new patient-fi
Radiotherapy After Chemo May Improve Survival in Advanced Hodgkin's Lymphoma Patients
News | Radiation Therapy | May 10, 2019
Patients with advanced Hodgkin's lymphoma who have large tumors at the time of diagnosis may benefit from radiotherapy...
IBA Partnering to Develop Advanced Digital Proton Therapy Technologies in Belgium
News | Proton Therapy | May 10, 2019
IBA (Ion Beam Applications SA) announced a research agreement with Skandionkliniken, Université Catholique de Louvain...